DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Objections
Claim 1 is objected to because of the following informalities: the bullet points “●” are not permitted and should be removed. The bulleted text should be separated by appropriate punctuation (e.g., semicolons or the like). Appropriate correction is required.
Claims 6-11 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim should refer to other claims in the alternative only. See MPEP § 608.01(n). Accordingly, the claims 6-8 and 11 have not been further treated on the merits.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-5 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Regarding claim 1, the claim does not end with a period “.”. Thus, the metes and bounds of the claim would have been unclear to one of ordinary skill in the art. Claims depending from claim 1 are rejected for reading upon an indefinite claim.
Regarding claim 3, the parenthetical phrase(s) “(sulphadoxine and sulphamethoxypyridazine)” and/or “(dipeptidyl vinyl sulfones and peptidomimetic pyrimidine nitriles)” render(s) the claim indefinite because it is unclear whether the limitations within the parentheses are part of the claimed invention. See MPEP § 2173.05(d).
Regarding claim 4, the parenthetical phrase(s) “(abexinostat…tubastatin A)” and/or “(MMA-E…and dolastatinol)”renders the claim indefinite because it is unclear whether the limitations within the parentheses are part of the claimed invention. See MPEP § 2173.05(d).
Conclusion
Claims 1-11 are pending. Claims 1-5 are rejected. Claims 6-11 are objected. No claims are allowed.
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Miranda, Daniela, et al. "Novel endoperoxide-based transmission-blocking antimalarials with liver-and blood-schizontocidal activities." ACS medicinal chemistry letters 5.2 (2014): 108-112 (Miranda) is representative of prior art. Miranda teaches tetraoxane-primaquine hybrids having formula
PNG
media_image1.png
258
686
media_image1.png
Greyscale
.
See Abstract. Miranda further teaches tetraoxane-primaquine hybrids 5-6, 8, 10, and 12 (Scheme 1).
PNG
media_image2.png
546
520
media_image2.png
Greyscale
Miranda does not teach or suggest a tetraoxane-primaquine hybrid wherein the linker is -OC(O)-. It would not have been obvious to modify a tetraoxane-primaquine hybrid of Miranda to arrive at an instantly claimed compound as prior art does not teach a suggest a structurally similar compound wherein the linker is -OC(O)-.
Contacts
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PATRICK T LEWIS whose telephone number is (571)272-0655. The examiner can normally be reached Monday to Friday, 10 AM to 4 PM EST (Maxi Flex).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/PATRICK T LEWIS/Primary Examiner, Art Unit 1691
/PL/
Prosecution Insights